Covid-19 vaccine: Key updates on which country stands where on development

Modesto Morganelli
Luglio 19, 2020

Human trials of a potential Covid-19 vaccine being developed by scientists in Oxford are reported to have shown promising results.

Hyderabad-based pharmaceutical company Bharat Biotech has collaborated with National Institute of Virology (NIV) and the Indian Council of Medical Research (ICMR) to develop the vaccine for the lethal virus. A report in the Hindustan Times said that BBIL said that the human trials of Covaxin started on July 15.

Asked about the concerns raised by AIIMS Ethics Committee a few days back regarding the trial, Dr Rai said that those concerns were addressed in the Ethics Committee meeting and the panel gave green signal to initiate the trial. It is to involve a total sample size of 1,125 healthy volunteers in two phases (phase 1 and 2), with 375 in phase-1 involving age groups of 18-55, and 750 volunteers in the age group 12-65 in phase-2 study.

China has positioned itself to be a strong contender.

"Nobody can put final dates... things might go wrong but the reality is that by working with a big pharma company, that vaccine could be fairly widely available around September and that is the sort of target they are working on".

With respect to CEPI's dose allocation, this will be subject to CEPI's equitable access obligations which require that the doses will be available first to populations at risk when and where they are needed, at prices both affordable to those populations and sustainable to CSL.

The Queensland government has struck a deal to secure 100 million vials of a vaccine if it is successfully developed by the University of Queensland.

The frenzied global purchasing of COVID-19 medical supplies has dominated Public Services and Procurement Canada for months now.

Eight of the almost two dozen potential vaccines in various stages of human testing worldwide are from China, the most of any country. In the second stage, 105 people are expected to be administered the vaccine. For that, the Phase-I of human clinical trials with 375 volunteers has now completed successfully. He further said that some people have already registered for this test.

Blood samples taken from a group of United Kingdom volunteers given a dose of the vaccine showed that it stimulated the body to produce both antibodies and "killer T-cells", a senior source from the trial was quoted by "The Daily Telegraph" as saying. The three arms of the study are blinded, so neither participant nor clinical staff will know which dose they have received.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE